Cell and gene therapies (CGTs) hold promise for the treatment of a variety of diseases including cancer and rare genetic disorders such as sickle-cell disease. Many of these therapies involve the genetic engineering of cells in order to insert exogenous sequences or alter existing genes. After the cells are altered, they are introduced into the patient where they either replace dysfunctional cells or provide a desired immune response. The use of engineered cells for human therapies requires sensitive and robust characterization of genomic manipulations, which are typically achieved through viral transduction or the use of gene editors, such as CRISPR.
All methods of genetic engineering yield cell populations with genetic heterogeneity. For instance, there may be cell-to-cell variability in transduction efficiency and copy number (for viruses), or for on- and off-target editing efficiencies (for gene editors). Because unintended genomic alterations may have consequences to the efficacy and safety of therapeutic agents, it is imperative that engineered cells be characterized with a high degree of accuracy and sensitivity. Measuring genomic manipulations at a single-cell level provides the most robust characterization of CGT products.
Register for this webinar to hear Shu Wang, Ph.D., and Matthew Cato from Mission Bio will discuss how highly sensitive single-cell DNA sequencing (scDNA-seq) on the Tapestri Platform accelerates CGT workflows. They will discuss the advantages of Tapestri for the quantification of cell-specific alterations achieved through viral vectors and gene editors, and contrast this approach to conventional multi-assay processes. They will also explain how integrating Tapestri into the CGT pipeline —from development to manufacturing and release testing — consolidates workflows and accelerates bringing breakthrough therapies to market. Lastly, Shu and Matthew will discuss how Mission Bio’s Pharma Assay Development (PAD) service enables biopharmaceutical companies to seamlessly evaluate and integrate single-cell technology into their current CGT programs.
Shu Wang, PhD, Associate Director, Bioinformatics, Mission Bio
Shu Wang, PhD, is a bioinformatics scientist who specializes in single-cell DNA NGS and multi-omics assay development and data analysis. She has expertise in building bioinformatics solutions for NGS platforms and providing biology insights from massive data analysis for oncology and genomics studies.Message Presenter
Matthew Cato, Director, Cell and Gene Therapy, Mission Bio
Matthew Cato is a business and market development leader who specializes in cell and gene therapies and precision medicine. With a background in immunology and biotechnology, he focuses on strategic commercial development for single-cell technology to advance cell and gene therapeutic solutions.Message Presenter
Who Should Attend?
- Cell & Gene Therapy R&D/Manufacturing/QC
- Biopharma Executives/R&D/Sponsors
What You Will Learn
In this webinar, participants will learn about:
- The integration of single-cell analysis into CGT development and production workflows
- The measurement of genomic alterations from thousands of single cells without the need for lengthy cell outgrowth protocols
- How more parameters are measured from a single assay than in conventional methods of CGT analysis
- How Mission Bio’s Pharma Assay Development (PAD) accelerates the time to market of CGTs
Mission Bio is a life sciences company that accelerates discoveries and cures in oncology by equipping researchers with the ability to measure multi-omics at single-cell resolution. The company’s Tapestri Platform gives researchers worldwide the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Partnering with pharma and biopharma companies, Mission Bio implements proven single-cell multi-omics capabilities into discovery, translational, and clinical research efforts. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.